Promising new drugs seen in technologies of genetics

Had there be enough medications and treatment when he was young, 42-year-old Guan Tao would not have had deformed legs because of hemophilia, an inherited blood disorder.

The Beijing resident later founded the Hemophilia Home of China, a non-governmental organization to support patients who need clotting factors to prevent severe blood loss and near-constant complications.

Nowadays, though foreign companies have been using gene-related technologies to produce medications for hemophilia since the 1990s, Chinese companies are only capable of extracting clotting factors from blood, and under current Chinese policies, it takes years for foreign drugs to launch in Chinese market, Guan says.